multiple myeloma

The European Medicines Agency's CHMP recommended conditional approval of Janssen, a unit of Johnson & Johnson (NYSE: JNJ), and its partner Legend Biotech Corporation's (NASDAQ: LEGN) CAR-T therapy to treat multiple myeloma. The drug, Carvykti (...

Allogene Therapeutics Inc (NASDAQ: ALLO) announced the publication of preclinical study results demonstrating the superior long-term in vitro myeloma-killing activity of allogeneic anti-BCMA CAR T cells from healthy donors compared with cells from multiple myeloma patients...

2seventy bio Inc's (NASDAQ: TSVT) anti-BCMA CAR-T got axed as part of a corporate update. The treatment was under development in collaboration with Bristol Myers Squibb Co (NYSE: BMY). 2seventy bio said the treatment, known as bb21217, will not undergo further development...

Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at the American Society of Hematology (ASH) 2021 Annual Meeting. With approvals already in place as triplet therapies,...

Harpoon Therapeutics Inc (NASDAQ: HARP) presented a poster with interim data from the ongoing dose-escalation portion of the Phase 1/2 trial for HPN217 in patients with relapsed/refractory multiple myeloma. Data were presented at the American Society for Hematology (ASH) Annual...

Janssen, a unit of Johnson & Johnson (NYSE: JNJ), posted longer-term results from the Phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy for relapsed / refractory...

SpringWorks Therapeutics Inc (NASDAQ: SWTX) entered into a clinical trial collaboration agreement with AbbVie Inc (NYSE: ABBV) to evaluate SpringWorks' nirogacestat combination with ABBV-383 in relapsed or refractory multiple myeloma. Gamma secretase inhibition helps...

ITeos Therapeutics Inc (NASDAQ: ITOS) posted new preclinical data for its anti-TIGIT monoclonal antibody, EOS-448, at the American Society of Hematology (ASH) Annual Meeting & Exposition and the TIGIT Therapies Digital Summit 2021. Data at the ASH 2021 demonstrated the efficacy...

Legend Biotech Corporation's (NASDAQ: LEGN) collaborating partner Janssen Pharmaceutical has submitted a marketing application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for ciltacabtagene autoleucel (cilta-cel). Cilta-cel is a B-...

Johnson & Johnson's (NYSE: JNJ) Janssen Biotech Inc has received FDA approval for Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with Amgen Inc's (NASDAQ: AMGN) Kyprolis (carfilzomib) and dexamethasone (Kd) for multiple myeloma. The combo...

The FDA granted Orphan Drug Designation for Gracell Biotechnologies Inc's (NASDAQ: GRCL) GC012F, FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for multiple myeloma. The long-term follow-up data for GC012F was presented in June at the ASCO 2021 Annual Meeting...

The FDA has cleared Poseida Therapeutics Inc (NASDAQ: PSTX) Investigational New Drug (IND) application for P-BCMA-ALLO1, a fully allogeneic CAR-T product candidate for relapsed/refractory multiple myeloma. The Phase 1 study will assess safety, tolerability, and response. The study...

New guidance from the National Institute for Health and Care Excellence (NICE) has rejected a combination regimen based on Johnson & Johnson's (NYSE: JNJ) Darzalex for previously untreated patients with multiple myeloma. The draft document covers the use of...

The European Commission (EC) has granted conditional marketing approval for Bristol Myers Squibb & Co's (NYSE: BMY) Abecma (idecabtagene vicleucel, ide-cel) for relapsed and refractory multiple myeloma. Abecma is a first-in-class B-cell maturation antigen (BCMA)-...

The FDA has granted Orphan Drug Designation to Allogene Therapeutics Inc's (NASDAQ: ALLO) ALLO-715 to treat multiple myeloma. In April 2021, ALLO-715 received Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA. ALLO-715, an AlloCAR T therapy targeting B-...